一种新型海洋纤溶酶的分离纯化与性质鉴定

doi:Q819

中国生物工程杂志

2010, Vol. 30

Issue (08): 47-51 DOI: Q819

研究报告

一种新型海洋纤溶酶的分离纯化与性质鉴定

王佃亮^1,2**,姜合作¹,王瑞玲¹,刘万顺²,张艳梅¹,孙晋伟¹

1.第二炮兵总医院中心实验室北京 100088
2.海洋生物工程系中国海洋大学青岛 266003

Purification and Characterization of a Novel Fibrinolytic Enzyme from a marine animal,Urechis unicinctus

WANG Dian-liang^1,2**,JIANG He-zuo¹,WANG Rui-ling¹,LIU Wan-shun²,ZHANG Yan-mei¹,SUN Jin-wei¹

1.Central Laboratory, the Second Artillery General Hospital, PLA, Beijing 100088,China
2.Department of Marine Bioengineering, Ocean University of China, Qingdao 266003, China

全文: PDF(521 KB) HTML

摘要：

单环刺螠生活在近海泥沙地区的潮间带和低潮带，自1940年分类后曾归属于螠虫动物门，但是现在越来越认为它是多毛纲环节动物的一个分支。系统研究表明，单环刺螠的体腔液和内脏中含有高活性的溶栓物质，并从这两种组织中通过离心、过滤、硫酸铵盐析、超滤、Q. Sepharose Fast Flow、 Sephadex G-75 、Sephacry S-100等步骤分离到了一种纤溶酶UFE，SDS-PAGE聚丙烯酰胺凝胶电泳测得分子量为10.38 kDa. 利用尿激酶和PBS作对照的功能研究表明，UFE主要是直接降解纤维蛋白，但也表现部分激酶活性，这跟来自环节动物蚯蚓的蚓激酶一样，靠将纤维蛋白溶酶原转化为纤维蛋白溶酶降解纤维蛋白。研究表明，UFE是一种免疫原性小、纤溶能力强的具有潜在应用价值的溶栓剂。

关键词： 单环刺螠; 海洋蠕虫; 纤溶酶; 溶栓剂; 血栓性疾病

Abstract:

Urechis unicinctus living in the inter-tidal and hypotidal zone of the lower coastal mud-sand areas is a member of the group of worms classified as the Phylum Echiura since 1940, but increasingly thought to represent a clade within the polychaete annelids. A systematically analysis revealed that the highest thrombolytic activity was found in the haemocoelomic fluid and gut. Therefore the isolation of fibrinolytic enzyme (UFE)was undergone from the two tissues by centrifugation, filtration, ammonium sulfate precipitation, ultrafiltration, and chromatographic steps, including Q. Sepharose Fast Flow, Sephadex G-75, and Sephacry S-100. UFE was finally purified approximately 11 fold with a yield of 29.82%. UFE appeared to be homogenous by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with a low molecular weight of about 10.38 kDa.

Functional studies showed that using urokinase (UK) as a positive control and phosphate buffer saline (PBS) as a negative control, UFE mainly hydrolyzed fibrin directly, but it also exihibited some UK activity. UFE appeared to degrade fibrin by transformation of plasminogen into plasmin, which was similar to lumbrokinase from different earthworms, whereas UK did not directly hydrolyze fibrin without the presence of active plasminogen. These suggest that UFE is a potent thrombolytic agent with less immunogenicity and strong fibrinolysis for treatment of thrombosis.

Key words: Urechis unicincts Marine worm Fibrinolytic enzyme Thrombolytic agent Thrombotic disease

收稿日期: 2010-03-18 出版日期: 2010-08-25

基金资助:

国家“863”计划(2001AA625050)、国家“十五”重点科技计划(2001BA708B04-07)资助项目

通讯作者: 王佃亮 E-mail: wangdianl@sina.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王佃亮
	姜合作
	王瑞玲
	刘万顺
	张艳梅
	孙晋伟

引用本文:

王佃亮姜合作王瑞玲刘万顺张艳梅孙晋伟. 一种新型海洋纤溶酶的分离纯化与性质鉴定[J]. 中国生物工程杂志, 2010, 30(08): 47-51.

WANG Dian-Liang, JIANG Ge-Zuo, WANG Rui-Ling, LIU Mo-Shun, ZHANG Yan-Mei, SUN Jin-Wei. Purification and Characterization of a Novel Fibrinolytic Enzyme from a marine animal,Urechis unicinctus. China Biotechnology, 2010, 30(08): 47-51.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/Q819 或 https://manu60.magtech.com.cn/biotech/CN/Y2010/V30/I08/47

［1］ Yu I T S, Li W, Wong T W. Effects of age, period and cohort on acute myocardial infarction mortality in Hong Kong. Int J Cardiol, 2004, 97: 63 68.
［2］ Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta,2003,330: 3155.
［3］ Lostaoa L, Regidorb E, Aiachc P, et al. Social inequalities in ischaemic heart and cerebrovascular disease mortality in men: Spain and France,1980~1982 and 1988~1990. Soc Sci Med, 2001,52:18791887.
［4］ Segel G B, Charles W F. Anticoagulant proteins in childhood venous and arterial thrombosis: a review. Blood Cells Mol, Dis,2000, 26(5): 540–560.
［5］ Yang T Y, Chung K J, Huang T L, et al. Massive pulmonary embolism in a young patient on clozapine therapy. J Emerg Med,2004, 27(1) 2729.
［6］ Ginsberg J S. Antithrombotic therapy in children. Thromb. Res, 2003,109: 83.
［7］ Sobol S E, Elden L M, Wetmore R F. Management of lateral sinus thrombosis in children. Otolaryngol. Head Neck Surg, 2004,240.
［8］ Temple M, Williamsb S, Johna P, et al. Percutaneous treatment of pediatric thrombosis. Eur J Radiol,2005,53:1421.
［9］ Kobayashi T, Shinohara M, Tomomasa T, et al. Percutaneous hydrodynamic thrombectomy for femoral arterial thrombosis after arterial catheterization. Pediatr Cardiol,2003, 24(4):409411.
［10］ Rasche H. Haemostasis and thrombosis: an overview. Eur Heart J Suppl,2001, 3 (Supplement Q): Q3–Q7.
［11］ Klocker J, Perkmann R, KleinWeigel P, et al. Continuous administration of heparin in patients with dee Pvein thrombosis can increase plasma levels of diamine oxidase. Vascul Pharmacol, 2004,40: 293300.
［12］ Helft G, Worthley S G. Antithrombotic, antiplatelet and fibrinolytic therapy: current management of acute myocardial infarction. Heart Lung Circ,2001,10: 6874.
［13］ Atkinson R P, DeLemos C. A cute ischemic stroke management. Thromb Res, 2000,98: V97V111.
［14］ Merlini P A, Cugno M, Rossi M L, et al. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol, 2004,93: 822 825.
［15］ Sumino H, Ichikawab S, Sawadab Y, et al. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women Thromb Res, 2005,115:359366.
［16］ Shackelford D P, Lalikos J F. Estrogen replacement therapy and the surgeon. Am J Surg, 2000,179:333336.
［17］ Mannucci P M. Venous thromboembolism and hormone replacement therapy. J Intern Med, 2001,12:478483.
［18］ Factor P. Gene therapy for acute diseases. Mol Ther,2001, 4(6):515524.
［19］ Glickman. 21st century thrombolytic use. J Radiol Nurs, 2005,24 (2):35.
［20］ Banerjee A, Chisti Y, Banerjee U C. Streptokinase—a clinically useful thrombolytic agent. Biotechnol Adv, 2004,22:287–307.
［21］ Yilmaz M B, Akin Y, Guray U, et al. Spontaneous rectus muscle hematoma following streptokinase therapy for acute myocardial infarction: a case report. International Int J Cardiol,2002,84:101–103.
［22］ Uszynski M, Perlik M, Uszynski W, et al. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues Measurements and clinical implications. Eur J Obstet Gynecol Reprod Biol,2004,114:54–58.
［23］ Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol,2004,25(8): 450455.
［24］ Kent D M, Vijan S, Hayward R A, et al. Tissue plasminogen activator was costeffective compared to streptokinase in only selected patients with acute myocardial infarction. J Clin Epidemiol, 2004,57:843–852.
［25］ Rouf S A, MooYoung M Chisti. Tissuetype plasminogen activator: characteristics, applications and production technology. Biotechnol Adv, 1996,14(3): 239266.
［26］ Wang P, Zhang J, Sun Z, et al. Glycosylation of prourokinase produced by Pichia pastoris impairs enzymatic activity but not secretion. Protein Expr Purif,2000, 20:179–185.
［27］ Hua Z C, Dong C, Zhu D X. Renaturation of recombinant human prourokinase expressed in Escherichia coli. Biochem. Biophys Res Commun,1996, 220:131–136.
［28］ Gurewich. Prourokinase mutants. Enzyme Microb Technol, 1996,19:130.
［29］ Davydov L, Cheng J W M. Tenecteplase: a review. Clin Ther, 2001,23(7):982997.
［30］ Sanchez E F, Bush L R, Swenson S, et al. Chimeric fibrolase: covalent attachment of an RGDlike peptide to create a potentially more effective thrombolytic agent,1997,87(3):289302.
［31］ Torchilin V P. Targeting of drugs and drug carriers within the cardiovascular system. Adv Drug Deliv Rev,1995, 17:75101.
［32］ Petri T, Langer G, Bringmann P, et al. Production of vampire bat plasmnogen activator DSPA α1 in CHO and insect cells. J Biotechnol,1995,39: 7583.
［33］ Nakajima N, Sugimoto M, Ishihara K. Earthwormserine protease: characterization, molecular cloning, and application of the catalytic functions. J Mol Catal, B Enzym,2003, 23:191–212.
［34］ Lahteenmaki K, Kuusela P, Korhonen T K. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev,2001, 25: 531552 .
［35］ Chisholm J R S, Smith V J. Comparison of antibacterial activity in the hemocytes of different crustacean species. Comp. Biochem Physiol,1995,110A (1):3945.
［36］ Yokokawa F, Sameshima H, In Y, et al. Total synthesis and conformational studies of ceratospongamide, a bioactive cyclic heptapeptide from marine origin. Tetrahedron ,2002,58:8127–8143.
［37］ Shahidi F, JanakKamil Y V A. Enzymes from fish and aquatic invertebrates and their application in the food industry. Trends Food Sci Technol,2001,12: 435464.
［38］ Zhang Z F, Shao M Y, Kang K H, et al. Studies on the tolerating mechanism for sulfide in Urechis unicinctus (Echiura: urechidae): Cytological observation on Urechis unicinctus in different hydrogen sulfide environment. Chin J Oceanol Limnol,2003, 21(1): 8690.
［39］ Hu R L, Zhang S F, Liang H Y, et al. Codon optimization, expression, and characterization of recombinant lumbrokinase in goat milk. Protein Expr Purif,2004, 37:83–88.
［40］ Tang Y, Liang D C, Jiang T, et al. Crystal structure of earthworm fibrinolytic enzyme component A: revealing the structural determinants of its dual fibrinolytic activity. J Mol Biol,2002, 321: 5768.
［41］ Zhao J, Li L, Wu C, et al. Hydrolysis of fibrinogen and plasminogen by immobilized earthworm fibrinolytic enzyme II from Eisenia fetida. Int J Biol Macromol, 2003,32:165–171.
［42］ Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem, 1976,72:248254.
［43］ Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys, 1952,40:346351.
［44］ Mcdonald C E, Chen L L. The Lowry modification of the folin reagent for determination of proteinase activity. Anal Biochem,1965,10: 175177.
［45］ Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature,1970, 227 :680685.
［46］ Liang J F, Li Y. Yang Y C. The potential mechanism for the effect of heparin on tissue plasminogen activator–mediated plasminogen activation. Thromb Res, 2000,97:349–358.
［47］ Khorana A A, Fine R L. Pancreatic cancer and thromboembolic disease. Lancet Oncol,2004,5: 655–663.
［48］ Kearon C, Gent M. Heparin therapy for dee Pvein thrombosis: from hospital to home. Am J Med,2001,110:501–502.
［49］ Govindaraju K, Srinivas H. Studies on the effects of enzymatic hydrolysis on functional and physicochemical properties of arachin. LWT,2004,39(2006):54–62.
［50］ Wu C, Li L, Zhao J, et al. Effect of a 2M on earthworm fibrinolytic enzyme III1 from Lumbricus rubellus. Int J Biol Macromol, 2002,31:7177.
［51］ Fan Q, Wu C, Li L, et al. Some features of intestinal absorption of intact fibrinolytic enzyme III1 from Lumbricus rubellus. Biochim Biophys Acta,2001,1526:286292.
［52］ Yang J S, Ru B G. Purification and characterization of an SDSactivated fibrinolytic enzyme from Eisenia fetida. Comp. Biochem Physiol,1997,118B (3): 623631.
［53］ Wang C, Wang F, Lia M, et al. Structural basis for broad substrate specificity of earthworm fibrinolytic enzyme component A. Biochem Biophys Res Commun, 2004,325:877–882.
［54］ Wang F, Wang C, Li M, et al. Crystal structure of earthworm fibrinolytic enzyme component B: a novel, glycosylated twochained trypsin. J Mol Biol,2005,348(6):671685.
［55］ Düsterhft E M, Linssen V A J M, Voragen A G R, et al. Purification, characterization, and properties of two xylanases from Humicola insolens. Enzyme Microb Technol, 1997,20: 437445.

[1]	王瑜,刘治,白文成,许丽萍,韩润林. 重组不可分型流感嗜血杆菌E蛋白与血浆脂蛋白(a)的相互作用[J]. 中国生物工程杂志, 2017, 37(12): 14-20.
[2]	钱辉, 张充, 陆兆新, 别小妹, 赵海珍, 吕凤霞. 内生多粘芽孢杆菌EJS-3纤溶酶基因在毕赤氏酵母中的表达[J]. 中国生物工程杂志, 2014, 34(12): 45-50.
[3]	刘玉芬, 冬黎黎, 孙玉刚, 刘鹏, 陈辉, 赵文阁. 中介蝮蛇毒纤溶酶基因真核表达载体的构建及其功能的研究[J]. 中国生物工程杂志, 2012, 32(10): 1-6.
[4]	陈武莫炜张艳玲宋钢宋后燕. 重组人纤溶酶原基因的酵母表达、产物纯化及鉴定[J]. 中国生物工程杂志, 2009, 29(10): 18-22.
[5]	王高学,梁朝军,黄海洪,王建福,原居林. 嗜麦芽寡养单胞菌(DR-929)纤溶酶的发酵条件优化及其分离纯化[J]. 中国生物工程杂志, 2007, 27(9): 47-52.
[6]	张守涛,周雁胜,包星峰,郭蔼光. 蛇毒纤溶酶Alfimeprase在大肠杆菌中的可溶表达和纯化[J]. 中国生物工程杂志, 2006, 26(03): 31-36.
[7]	付大雁, 赵伟, 郭锴, 俞军. 五步蛇蛇毒的分离纯化及综合利用[J]. 中国生物工程杂志, 2005, 25(7): 98-99,107.
[8]	黄红艳, 孙强, 李庆霞, 刘家云, 王凯, 鲍炜, 贾林涛, 王成济, 杨安钢. 针对uPA的siRNA对人乳腺癌细胞侵袭的抑制作用[J]. 中国生物工程杂志, 2005, 25(6): 31-35.
[9]	耿旭, 李骏, 左翼, 吴自荣. 亚硝酸钠体外随机突变枯草杆菌纤溶酶基因及其产物性质研究[J]. 中国生物工程杂志, 2005, 25(6): 61-64.
[10]	安靓, 李振林, 黄伟民, 黄吴建, 李进. 乳腺注射法表达人组织型纤溶酶原激活剂的研究[J]. 中国生物工程杂志, 2004, 24(11): 42-45.
[11]	卞慧芳, 黄静, 左翼, 郁正艳, 吴自荣. 重组枯草杆菌纤溶酶的酶学性质研究[J]. 中国生物工程杂志, 2004, 24(10): 80-83.
[12]	牛勃, 陈显久, 张东昌, 解军, 张悦红, 杨琦, 程牛亮. 人纤溶酶原饼环区5(hPK5)基因的分泌型表达[J]. 中国生物工程杂志, 2003, 23(9): 91-95.
[13]	任启生, 陈黄实, 宋新荣, 李伯松. 刺桐胰蛋白酶抑制剂基因的构建及表达研究[J]. 中国生物工程杂志, 2003, 23(7): 102-104.
[14]	陈丽娟, 沙长青, 任永春, 奚新伟, 王佳龙. 纳豆激酶溶解血栓机制[J]. 中国生物工程杂志, 2003, 23(4): 53-56.
[15]	李世崇, 胥照平, 胡显文, 张正光, 高丽华, 肖成祖. 重组人尿型纤溶酶原激活剂的中试生产与性质研究[J]. 中国生物工程杂志, 2003, 23(3): 55-58.

Viewed

Full text

Abstract

Cited

Shared

Discussed